This article is part of a series on The World Antimalarial Resistance Network (WARN), edited by Carol Hopkins Sibley.  ReviewWorld Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malariaChristopher V Plowe1 1Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1-480, Baltimore, Maryland 21201 USA 2London School of Hygiene and Tropical Medicine, Keppel Street, London, UK WC1E 7HT 3Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE MS F-13, Atlanta, Georgia 30341 USA 4Department of Immunology and Infectious Diseases, Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115 USA 5National Institute of Malaria Research, 22 Sham Nath Marg, Delhi 110054, India 6Biotechnology Centre, University of Yaounde I, Cameroon, Box 8094 Yaounde, Cameroon 7University of North Carolina Schools of Public Health and Medicine, Chapel Hill, North Carolina 27599 USA 8Ifakara Health Research and Development Centre, P. O. Box 53, Ifakara, Tanzania 9Malaria Research Programme, Medical Research Council, PO Box 70380, Overport, 4067, South Africa 10International Health Programme, Menzies School of Health Research, P. O. Box 41096, Casuarina, Darwin, NT 0811 Australia 11Division of Infectious Diseases, Room S-169, Stanford University Medical Center, 300 Pasteur Drive, Stanford, California 94305 USA 12Department of Genome Sciences, Box 355065, University of Washington, Seattle, Washington 98195 USA 13London School of Hygiene & Tropical Medicine, Department of Infectious and Tropical Diseases, Immunology Unit, Keppel Street, London WC1E 7HT, UK 14Case Western Reserve University, The Center for Global Health & Diseases, Wolstein Research Building, Room 4-125, 2103 Cornell Road, Cleveland, Ohio 44106 USA 15University of California San Francisco, Box 0811, San Francisco, California 94143 USA
Malaria Journal 2007, 6:121doi:10.1186/1475-2875-6-121
AbstractMolecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs. |
|
|
|
 |   | Log on / register BioMed Central home | Journals A-Z | Feedback | Support | My details |
on Google Scholar
author email
corresponding author email|
|
| © 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. |